David Hutton is an Executive Editor for Optometry Times and Ophthalmology Times. With a focus on eye health and ophthalmology, David covers topics such as pharmaceutical advancements, clinical trials, new treatments, and industry news. He brings a wealth of knowledge and expertise to his articles, keeping readers informed on the latest developments in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
David Hutton's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly in ophthalmology, eye diseases, clinical trials, FDA approvals, and medical technology. His articles primarily consist of press releases and data citations from private sector announcements.
For reaching out to David with a pitch or as a source for an article related to his coverage area, consider offering new scientific research findings in ophthalmology or developments in medical technology aimed at treating eye diseases. Also relevant are updates on ongoing clinical trials or recent FDA approvals related to eye care.
Given that he appears to cover a wide range of topics within the healthcare and pharmaceutical industry without specifying any geographic focus, pitches should emphasize global relevance rather than regional specificity.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.
The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.
The American Academy of Ophthalmology indicates that consumers who may see the eye color-changing drops advertised and used on TikTok or elsewhere online should be advised that they are not FDA approved.
A team of researchers from Johns Hopkins Medicine and the University of Wisconsin-Madison conducted a study on the application of autonomous artificial intelligence and testing for diabetic eye disease.
By: David Hutton
A team of researchers at the Center for Regenerative Therapies Dresden of Dresden University of Technology is working to develop a method to replace or regenerate damaged photoreceptor cells in the human retina.
By: David Hutton
Investigators at the Dean McGee Eye Institute reviewed the accuracy of the tools in measuring 5 vision assessment parameters, including distance visual acuity, near visual acuity, color vision testing, contrast sensitivity, and pupillary distance.
By: David Hutton
Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.
By: David Hutton
BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
By: David Hutton
In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
(833) 317-6278 
